Trial Profile
Safety and Efficacy of the Early Introduction of Everolimus (Certican) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 18 Nov 2015 New trial record
- 30 Jun 2014 Primary endpoint of a composite variable of the incidence of efficacy failure including biopsy-proven acute rejection, graft loss, death, or loss to follow-up until 12 months after transplantation has not been met, according to results published in the Transplantation.